Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

BRAF V600E-mutant metastatic colorectal cancer (CRC) was associated with poor clinical outcomes in patients receiving ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

Pfizer (NYSE:PFE) announced Saturday that its colorectal cancer therapy Braftovi, as part of a combination regimen, reduced tumor size (confirmed objective response rate) in a late-stage trial with a ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...

Bristol Myers Squibb (BMY) says its cancer drugs Opdivo and Yervoy improved progression-free survival in a Phase 3 trial for ...

Successful test in breast cancer patients: the active agent digoxin, a cardiac medication, dissolves clusters of circulating breast cancer cells in the blood, thus reducing the risk of metastases ...

Successful test in breast cancer patients: the active agent digoxin, a cardiac medication, dissolves clusters of circulating ...